GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Median PS Value

Medexus Pharmaceuticals (TSX:MDP) Median PS Value : C$6.33 (As of Dec. 11, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Medexus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was C$5.778. Medexus Pharmaceuticals's 10-Year median PS Ratio is 1.0955. Therefore, the Median PS Value for today is C$6.33.

As of today (2024-12-11), Medexus Pharmaceuticals's share price is C$3.05. Medexus Pharmaceuticals's Median PS Value is C$6.33. Therefore, Medexus Pharmaceuticals's Price to Median PS Value for today is 0.48.

The historical rank and industry rank for Medexus Pharmaceuticals's Median PS Value or its related term are showing as below:

TSX:MDP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06   Med: 0.15   Max: 0.48
Current: 0.48

During the past 13 years, the highest Price to Median PS Value of Medexus Pharmaceuticals was 0.48. The lowest was 0.06. And the median was 0.15.

TSX:MDP's Price-to-Median-PS-Value is ranked better than
82.6% of 523 companies
in the Drug Manufacturers industry
Industry Median: 0.91 vs TSX:MDP: 0.48

Medexus Pharmaceuticals Median PS Value Historical Data

The historical data trend for Medexus Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Median PS Value Chart

Medexus Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 16.78 11.00

Medexus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.58 12.80 11.00 8.50 6.33

Competitive Comparison of Medexus Pharmaceuticals's Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Price-to-Median-PS-Value falls into.



Medexus Pharmaceuticals Median PS Value Calculation

Medexus Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=5.778*1.0955
=6.33

10-Year Median PS Ratio is 1.0955.
Medexus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$5.778.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medexus Pharmaceuticals  (TSX:MDP) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Medexus Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=3.05/6.33
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medexus Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Executives
Brendon Buschman Senior Officer
Benoit Gravel Director
Stephen William Nelson Director
Kenneth D'entremont Director, Senior Officer
Mike Mueller Director
Marcel Pascal Konrad Senior Officer
Brian Peters Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin Senior Officer
Michael Pine Senior Officer
Glenn Tate Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Richard Labelle Senior Officer
Benoît Hébert Senior Officer